SOLENO THERAPEUTICS INC

SLNO · Nasdaq · SIC 2834: Pharmaceutical Preparations
255
SEC Filings

Business Summary

PART I ITEM 1. B USINESS Company Overview We are a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. On March 26, 2025, we announced that our lead product candidate, VYKAT TM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, had been approved by the U.S. Food and Drug Administration (FDA). VYKAT XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). On Apr...

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSLNOdiscussed_in_filing Cybersecurity
topic_mentionSLNOdiscussed_in_filing Cybersecurity
topic_mentionSLNOdiscussed_in_filing Healthcare & Bio
topic_mentionSLNOdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-252025-12-310001193125-26-071808EDGAR73K words
2025-02-282024-12-310000950170-25-029545EDGAR—
2024-03-072023-12-310000950170-24-027500EDGAR—
2023-03-222022-12-310000950170-23-009211EDGAR—
2022-03-312021-12-310001564590-22-013023EDGAR—
2021-03-032020-12-310001564590-21-010569EDGAR—
2020-03-042019-12-310001564590-20-008705EDGAR—
2019-03-202018-12-310001564590-19-008508EDGAR—
2018-04-022017-12-310001193125-18-104048EDGAR—
2017-03-152016-12-310001628280-17-002603EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001193125-25-264941EDGAR51K words
2025-08-062025-06-300000950170-25-104220EDGAR—
2025-05-072025-03-310000950170-25-065675EDGAR—
2024-11-062024-09-300000950170-24-122276EDGAR—
2024-08-072024-06-300000950170-24-092713EDGAR—
2024-05-092024-03-310000950170-24-057109EDGAR—
2023-11-082023-09-300000950170-23-060438EDGAR—
2023-08-082023-06-300000950170-23-039934EDGAR—
2023-05-092023-03-310000950170-23-019752EDGAR—
2022-11-092022-09-300000950170-22-023838EDGAR—
2022-08-102022-06-300001564590-22-028965EDGAR—
2022-05-102022-03-310001564590-22-019266EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-060001193125-26-142911EDGAR67K words
2026-03-160001193125-26-107429EDGAR—
2026-02-260001193125-26-073209EDGAR—
2026-02-250001193125-26-071528EDGAR—
2026-01-230001193125-26-021229EDGAR—
2026-01-120001193125-26-009886EDGAR—
2025-11-120001193125-25-275674EDGAR—
2025-11-040001193125-25-264658EDGAR—
2025-10-140001193125-25-237854EDGAR—
2025-09-100001193125-25-199882EDGAR—

255 total filings indexed. 223 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001484565
TickerSLNO
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 6e863d27e53e8dcd7f377f43b3077eca3c45b9778260deffb8072d9398ec3131
parent: bbab8d5b6c1fb22dfeadac827c2a818b2723be76e034ea8c5389283e3966496e
content hash: 823cb74193328a3d622c1bdefb0679c112b2fa63dad346168d7ddd6894385d1f
signed: 2026-04-13T04:47:29.162Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf